Targeting a key protein to stop prostate cancer from spreading
Targeting Undruggable Transcription Factor HoxB13 to Inhibit Prostate Cancer Metastasis
['FUNDING_R01'] · DUKE UNIVERSITY · NIH-11065120
This study is testing a new gene therapy to help men with advanced prostate cancer that has spread, by targeting a specific factor that helps the cancer grow, with the hope of improving their treatment options and outcomes.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11065120 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new treatment approach for metastatic castration-resistant prostate cancer (mCRPC), which is a severe form of prostate cancer that has spread to other parts of the body. The study aims to target the HoxB13 transcription factor, which is linked to cancer growth and metastasis, using a novel gene therapy method. By utilizing a lipid nanoparticle system to deliver RNA-targeting technology, the researchers hope to inhibit the function of HoxB13 and improve patient outcomes. This innovative approach seeks to address the limitations of current therapies that have not significantly improved survival rates for mCRPC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic castration-resistant prostate cancer, particularly those with metastases in visceral organs.
Not a fit: Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced prostate cancer, potentially improving survival rates and quality of life.
How similar studies have performed: While targeting transcription factors has been challenging, this approach is innovative and represents a novel strategy in cancer treatment, with limited prior success in similar methodologies.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, QIANBEN — DUKE UNIVERSITY
- Study coordinator: WANG, QIANBEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer, androgen resistant prostate cancer